PDCD1 and breast carcinoma: Suggesting these findings may be relevant for patients with breast cancer, Beziaud et al. documented an increased frequency of CSCs in breast cancer patients 10 days after the initiation of an ICI targeting PD-1, as well as a positive correlation between CSC or BCAT1 signatures and IFNγ signatures, especially after treatment initiation [8].